February 3, 2025 06:45 AM EST

Pfizer says new colorectal cancer data could support full approval of Braftovi

Nicole DeFeudis

Editor

Pfizer’s Braftovi combo regimen helped prolong the lives of certain patients with previously untreated colorectal cancer, and the company hopes the results will support Braftovi …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer says new colorectal cancer data could support full approval of Braftovi

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Drug prices likely to soar due to Trump tariffs, pharma bodies warn

Drugmakers seize on biomarkers to test the FDA's rare disease shift

J&J’s Rybrevant gets CHMP backing weeks after FDA rejection

Exclusive: German biotech declares Phase 2 win for non-opioid drug for neuropathic pain

Irish startup reports mid-stage victory for short-acting psychedelic drug in depression

Updated: Novartis claims best earnings in years, validating shift to pure-play strategy

Pfiz­er says new col­orec­tal can­cer da­ta could sup­port full ap­proval of Braftovi

Editor

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Pfizer says new colorectal cancer data could support full approval of Braftovi